Updated: January 28, 2026
How to Help Your Patients Save Money on Azstarys (Dexmethylphenidate/Serdexmethylphenidate): A Provider's Guide to Savings Programs
Author
Peter Daggett

Summarize with AI
- Understanding the Azstarys Cost Landscape for Patients
- Tool #1: The CoriumCares Manufacturer Savings Program
- Tool #2: Prior Authorization — A Roadmap for Success
- Tool #3: Prescription Discount Cards for Uninsured or Underinsured Patients
- Tool #4: Patient Assistance Programs for Low-Income Patients
- Tool #5: When to Recommend a Lower-Cost Therapeutic Alternative
- Building Cost Awareness Into Your Prescribing Workflow
A provider's guide to helping patients save money on Azstarys (dexmethylphenidate/serdexmethylphenidate) in 2026, including savings cards and assistance programs.
Azstarys (serdexmethylphenidate/dexmethylphenidate) represents a meaningful pharmacological advance for patients with ADHD — but its brand-only status and cash price of $545–$598 per month create real financial barriers for many patients. As a prescriber, understanding and proactively addressing these cost barriers can significantly improve medication adherence and treatment outcomes. This guide provides a comprehensive overview of savings tools, insurance navigation strategies, and therapeutic alternatives to help every patient afford their ADHD treatment.
Understanding the Azstarys Cost Landscape for Patients
Before discussing savings tools, providers should understand the pricing context:
Retail (cash) price: $545–$598 for 30 capsules (the full retail price without insurance or savings programs)
With GoodRx: Approximately $445–$455 — helpful for uninsured patients or those whose insurance doesn't cover Azstarys
With CoriumCares (commercially insured): $60 or less per fill; first prescription $0; refills $25 with insurance or $50 without
With commercial insurance (no savings card): Varies widely; $0–$60 after deductible for patients on plans that cover Azstarys at a favorable tier
No generic available: No generic Azstarys exists; none expected until at least 2037
Tool #1: The CoriumCares Manufacturer Savings Program
The CoriumCares copay assistance program is the most impactful cost-reduction tool for eligible patients. Key details prescribers should know:
Eligibility: Commercial (private) insurance only. Patients covered by federal healthcare programs (Medicare, Medicaid, TRICARE, CHIP, or other government programs) are NOT eligible.
Benefit: $60 or less per fill for eligible commercially insured patients. First prescription: $0. Refills: $25 with insurance coverage or $50 without.
How to help patients enroll: Direct patients to azstarys.com or provide the Corium contact number: 1-800-910-8432. Enrollment can often be done online or at the pharmacy.
Critical note: The CoriumCares card reduces the patient's out-of-pocket cost but does not eliminate the need for prior authorization if your patient's plan requires it. PA must be obtained first.
Tool #2: Prior Authorization — A Roadmap for Success
Many commercial plans require prior authorization for Azstarys. A smooth PA process can unlock both coverage and eligibility for the CoriumCares savings card. Here's how to optimize PA success:
Check the formulary before the appointment. Review the patient's insurance formulary to understand what documentation is required for Azstarys PA at their specific plan.
Document step therapy completion. Many plans require evidence of prior trial and failure or intolerance of generic methylphenidate, dexmethylphenidate, or amphetamine formulations. Have this documentation in the chart.
Frame the clinical rationale clearly. Useful justifications for Azstarys include: smooth PK profile reducing peak-related adverse effects, prodrug design reducing abuse potential in patients with relevant risk factors, or specific PK advantages for patients with adherence challenges requiring once-daily dosing.
Use the CoriumCares bridge. While the PA is being processed, patients may be able to use the CoriumCares uninsured rate ($50/fill) as a bridge. Confirm this with the manufacturer.
Escalate to peer-to-peer if denied. A peer-to-peer conversation with the insurance medical reviewer can often overturn initial denials. This takes 15–20 minutes and is one of the highest-yield advocacy actions for your patients.
Tool #3: Prescription Discount Cards for Uninsured or Underinsured Patients
For patients without commercial insurance or for whom the CoriumCares card is not accessible, prescription discount services like GoodRx and SingleCare can reduce the cash price to approximately $445–$455 for 30 capsules. This is not as low as the CoriumCares copay, but significantly below the $545–$598 retail price. Patients cannot use a discount card and the CoriumCares card simultaneously — they should compare and choose the option offering the lower price.
Tool #4: Patient Assistance Programs for Low-Income Patients
For uninsured or Medicaid/Medicare patients who cannot afford Azstarys through any of the above pathways, contact Corium directly to inquire about patient assistance program (PAP) availability. Most major pharmaceutical manufacturers have income-based assistance programs for qualifying patients. Additionally, organizations like NeedyMeds.org and the Patient Advocate Foundation (patientadvocate.org) can help patients navigate financial assistance options.
Tool #5: When to Recommend a Lower-Cost Therapeutic Alternative
If cost remains a significant barrier despite the above programs — particularly for Medicare, Medicaid, or uninsured patients — a therapeutic switch to generic dexmethylphenidate ER (generic Focalin XR) may be the most practical path. This delivers the same active metabolite (dexmethylphenidate) and costs roughly $30–$150/month depending on strength and pharmacy. The PK profile differs (bimodal vs. smooth prodrug release), so patient counseling and dose recalculation are needed.
Other cost-effective alternatives include generic lisdexamfetamine (generic Vyvanse, available since 2023), generic methylphenidate ER (generic Concerta), and generic atomoxetine (generic Strattera, for non-stimulant appropriate patients).
Building Cost Awareness Into Your Prescribing Workflow
Proactively addressing cost at the point of prescribing dramatically improves medication adherence. Recommended workflow additions:
At every new Azstarys prescription, ask: "Do you have insurance that might cover this?" and "Do you know about the manufacturer savings card?"
Train staff to check formulary coverage and initiate PA paperwork proactively for Azstarys, especially for new patients
Keep a printed or digital reference card with the CoriumCares program details (azstarys.com, 1-800-910-8432) and a list of pharmacy-accessible discount cards to give to patients
Additionally, help patients locate pharmacies with Azstarys in stock before writing the prescription — saving them the frustration of cost barriers AND access barriers at once. medfinder for providers can help your patients locate Azstarys at nearby pharmacies before the prescription is even sent.
For more on helping patients find Azstarys in stock, see: How to Help Your Patients Find Azstarys In Stock: A Provider's Guide.
Frequently Asked Questions
CoriumCares is Corium's manufacturer copay assistance program for Azstarys. Commercially insured eligible patients pay $60 or less per fill (first prescription: $0; refills: $25 with insurance, $50 without). Medicare and Medicaid patients are not eligible. Patients can enroll at azstarys.com or by calling 1-800-910-8432. Many pharmacies can facilitate enrollment at the point of dispensing.
Most plans require: (1) a confirmed ADHD diagnosis, (2) documentation of prior trials and failure of or intolerance to generic methylphenidate or dexmethylphenidate formulations (step therapy), and (3) a clinical rationale for Azstarys specifically — such as tolerability advantages related to its smooth PK profile or its unique prodrug delivery mechanism. Check your patient's specific plan requirements, as these vary by insurer.
Generic dexmethylphenidate ER (the generic of Focalin XR) is the most pharmacologically similar and cost-effective alternative to Azstarys. It delivers the same active compound (dexmethylphenidate) and costs $30–$150 per month depending on dose and pharmacy. Note that the two are not bioequivalent — do not substitute milligram-for-milligram. Titrate from standard starting doses after switching. Generic lisdexamfetamine (Vyvanse) is another once-daily prodrug alternative, available at a lower cost than brand Azstarys.
Medicare and Medicaid patients are not eligible for the CoriumCares manufacturer copay card. For Medicare patients, check whether the plan's Part D formulary covers Azstarys, and explore whether the patient qualifies for the Low Income Subsidy (Extra Help) program. For Medicaid patients, check your state's Medicaid formulary — coverage and restrictions vary by state. Contact Corium directly to inquire about patient assistance program availability for low-income patients outside of CoriumCares.
As a Schedule II controlled substance, Azstarys is subject to DEA regulations that restrict how manufacturer samples can be distributed. Traditional free samples are generally not available for Schedule II medications. However, the CoriumCares program's $0 first prescription offer effectively serves a similar function for eligible commercially insured patients. Contact the Corium medical affairs team at 1-800-910-8432 for the most current information on any patient starter options available to prescribers.
Medfinder Editorial Standards
Medfinder's mission is to ensure every patient gets access to the medications they need. We are committed to providing trustworthy, evidence-based information to help you make informed health decisions.
Read our editorial standardsPatients searching for Dexmethylphenidate/Serdexmethylphenidate also looked for:
More about Dexmethylphenidate/Serdexmethylphenidate
30,515 have already found their meds with Medfinder.
Start your search today.





